First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma

被引：1
|
作者：
Tsimafeyeu, Ilya [1 ]
Tjulandin, Sergei [1 ]
机构：
[1] Russian Soc Clin Oncol, Moscow, Russia
来源：
BJU INTERNATIONAL | 2019年 / 123卷 / 04期
关键词：
urothelial carcinoma; atezolizumab; pembrolizumab; cisplatin-ineligible patients; PD-L1; testing; CISPLATIN-INELIGIBLE PATIENTS; SINGLE-ARM; MULTICENTER; ATEZOLIZUMAB; CHEMOTHERAPY;
D O I：
10.1111/bju.14627
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：563 / 565
页数：3
相关论文
共 50 条
  • [21] Immune Checkpoint Inhibitors Plus Chemotherapy as First-Line Treatment in Patients with Advanced Pulmonary Sarcomatoid Carcinoma
    Wu, F.
    Du, H.
    Chen, S.
    Li, J.
    Gao, G.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S404 - S404
  • [22] Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma
    Alsina, Maria
    Fleitas-Kanonnikoff, Tania
    MED, 2024, 5 (09): : 1038 - 1040
  • [23] PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis
    Ghate, Ketan
    Amir, Eitan
    Kuksis, Markus
    Hernandez-Barajas, David
    Rodriguez-Romo, Laura
    Booth, Christopher M.
    Vera-Badillo, Francisco E.
    CANCER TREATMENT REVIEWS, 2019, 76 : 51 - 56
  • [24] Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma
    Lapuente, Maria
    Conway, Dawn
    Wood, Laura S.
    Kehoe, Kiran
    Bullock, Andrea Carroll
    Devgan, Geeta
    Burns, Kathleen D.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2023, 27 (01) : 71 - 80
  • [25] Systematic review of pembrolizumab vs. chemotherapy in PD-L1-positive advanced NSCLC as first line of treatment
    Atmadji, W.
    Arivia, C.
    Sidharta, F.
    Triaswhoro, G. Lintang
    Sito, W. Winston
    Angelius, C.
    Huang, I.
    Kurniawan, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1378 - S1379
  • [26] The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma
    Han, Fuxin
    Wu, Zhaozhen
    Chen, Jiaxin
    Liu, Meicen
    Hu, Yi
    CANCER MEDICINE, 2023, 12 (23): : 21129 - 21137
  • [27] Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs).
    Mantia, Charlene
    Jegede, Opeyemi
    Regan, Meredith M.
    Atkins, Michael B.
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China
    Liu, Shixian
    Jiang, Nana
    Dou, Lei
    Li, Shunping
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [29] Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis
    Monteiro, Fernando Sabino Marques
    Soares, Andrey
    Mollica, Veronica
    Leite, Caio Abner
    Carneiro, Andre Paterno Castello Dias
    Rizzo, Alessandro
    Bourlon, Maria T.
    Sasse, Andre Deeke
    Santoni, Matteo
    Gupta, Shilpa
    Massari, Francesco
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 196
  • [30] PHASE 3 STUDY OF FIRST-LINE PEMBROLIZUMAB WITH AND WITHOUT VIBOSTOLIMAB (ANTI-TIGIT) IN PATIENTS WITH PD-L1-POSITIVE METASTATIC NSCLC
    Hellmann, Matthew
    Cho, Byoung
    Juergens, Rosalyn
    Cheng, Ying
    de Castro, Gilberto
    Erman, Mustafa
    Bauman, Jessica
    Takahashi, Toshiaki
    Schwarzenberger, Paul
    Zhang, Pingye
    Pietanza, M. Catherine
    Yang, James Chih-Hsin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A488 - A488
12345